Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Soft Tissue Sarcoma and Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
At a glance
- Drugs AR 42 (Primary) ; Pazopanib (Primary)
- Indications Renal cell carcinoma; Soft tissue sarcoma
- Focus Adverse reactions
- 31 Jan 2018 Status changed from suspended to active, no longer recruiting.
- 03 Mar 2017 Planned End Date changed from 1 Jun 2025 to 30 Jun 2025.
- 03 Mar 2017 Planned primary completion date changed from 1 Mar 2019 to 30 Mar 2019.